Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001140361-19-018091
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-10-07 19:40:39
Reporting Period:
2019-10-07
Accepted Time:
2019-10-07 19:40:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1781983 Aprea Therapeutics Inc. APRE () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1765253 Versant Vantage I, L.p. One Sansome, Suite 3630
San Francisco CA 94104
No No No No
1777651 Versant Vantage I Gp, L.p. One Sansome Street, Suite 3630
San Francisco CA 94104
No No No No
1777653 Versant Vantage I Gp-Gp, Llc One Sansome Street, Suite 3630
San Francisco CA 94104
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-10-07 1,993,658 $0.00 2,006,328 No 4 C Indirect See footnotes
Common Stock Acquisiton 2019-10-07 512,995 $0.00 2,519,323 No 4 C Indirect See footnotes
Common Stock Acquisiton 2019-10-07 333,333 $15.00 333,333 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnotes
No 4 C Indirect See footnotes
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Convertible Preferred Stock Disposition 2019-10-07 1,993,658 $0.00 1,993,658 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2019-10-07 512,995 $0.00 512,995 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.
  2. These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.
  3. Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.
  4. These Shares are directly held by Versant Vantage I, L.P. Versant Vantage I GP-GP, LLC is the general partner of Versant Vantage I GP, L.P., which is the general partner of Versant Vantage I, L.P. Each of Versant Vantage I GP-GP, LLC and Versant Vantage I GP, L.P. may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage I, L.P., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.
  5. Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.